JP2021505131A - 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 - Google Patents

増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 Download PDF

Info

Publication number
JP2021505131A
JP2021505131A JP2020529376A JP2020529376A JP2021505131A JP 2021505131 A JP2021505131 A JP 2021505131A JP 2020529376 A JP2020529376 A JP 2020529376A JP 2020529376 A JP2020529376 A JP 2020529376A JP 2021505131 A JP2021505131 A JP 2021505131A
Authority
JP
Japan
Prior art keywords
cells
cell
car
receptor
ipsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505131A5 (https=
Inventor
バラマール，バーラム
ビョーダール，リャン
リー，トム，トング
ガイダロヴァ，スベトラナ
Original Assignee
フェイト セラピューティクス，インコーポレイテッド
フェイト セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェイト セラピューティクス，インコーポレイテッド, フェイト セラピューティクス，インコーポレイテッド filed Critical フェイト セラピューティクス，インコーポレイテッド
Publication of JP2021505131A publication Critical patent/JP2021505131A/ja
Publication of JP2021505131A5 publication Critical patent/JP2021505131A5/ja
Priority to JP2023192955A priority Critical patent/JP2024020364A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020529376A 2017-12-08 2018-11-30 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 Pending JP2021505131A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192955A JP2024020364A (ja) 2017-12-08 2023-11-13 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762596659P 2017-12-08 2017-12-08
US62/596,659 2017-12-08
US201862657626P 2018-04-13 2018-04-13
US62/657,626 2018-04-13
PCT/US2018/063362 WO2019112899A2 (en) 2017-12-08 2018-11-30 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192955A Division JP2024020364A (ja) 2017-12-08 2023-11-13 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法

Publications (2)

Publication Number Publication Date
JP2021505131A true JP2021505131A (ja) 2021-02-18
JP2021505131A5 JP2021505131A5 (https=) 2022-01-11

Family

ID=66749947

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529376A Pending JP2021505131A (ja) 2017-12-08 2018-11-30 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法
JP2023192955A Pending JP2024020364A (ja) 2017-12-08 2023-11-13 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192955A Pending JP2024020364A (ja) 2017-12-08 2023-11-13 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法

Country Status (12)

Country Link
US (1) US20210015859A1 (https=)
EP (1) EP3720946A4 (https=)
JP (2) JP2021505131A (https=)
KR (2) KR102938303B1 (https=)
CN (1) CN111556892A (https=)
AU (2) AU2018381191B2 (https=)
BR (1) BR112020010597A2 (https=)
CA (1) CA3083109A1 (https=)
IL (2) IL275180B1 (https=)
MX (1) MX2020005477A (https=)
SG (1) SG11202004833SA (https=)
WO (1) WO2019112899A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545992A (ja) * 2020-10-09 2023-11-01 フェイト セラピューティクス，インコーポレイティド 操作されたｉＰＳＣ及び装備された免疫エフェクター細胞
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
JP2025514709A (ja) * 2022-04-13 2025-05-09 ニューキオ バイオセラピューティクス（シャンハイ）カンパニー，リミテッド 細胞機能を増強するｃｄ１６切断耐性突然変異体

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL316257A (en) 2017-12-22 2024-12-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
PE20211959A1 (es) * 2019-02-15 2021-09-30 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
KR20210139472A (ko) * 2019-04-11 2021-11-22 페이트 세러퓨틱스, 인코포레이티드 조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성
CN114258429A (zh) * 2019-07-17 2022-03-29 菲特治疗公司 免疫效应细胞工程化和其用途
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
MX2022003414A (es) * 2019-09-25 2022-04-18 Fate Therapeutics Inc Celulas efectoras con multiples objetivos y uso de las mismas.
EP4041759A4 (en) * 2019-10-07 2023-12-20 Fate Therapeutics, Inc. IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL CULTURE AND USE THEREOF
AU2020364157A1 (en) * 2019-10-09 2022-04-14 Bluerock Therapeutics Lp Cells with sustained transgene expression
EP4045539A4 (en) * 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
US20230016034A1 (en) * 2019-12-06 2023-01-19 Fate Therapeutics, Inc. ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS
EP3858999A1 (en) * 2020-01-30 2021-08-04 Aelian Biotechnology GmbH Safe harbor loci
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
TW202206460A (zh) * 2020-04-24 2022-02-16 荷蘭商美勒斯公司 使用結合lgr5及egfr之抗體的癌症治療
CN116018158A (zh) * 2020-04-30 2023-04-25 转化基因组学研究所 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
CN113801238A (zh) * 2020-06-11 2021-12-17 南京北恒生物科技有限公司 表达nk抑制性分子的工程化免疫细胞及其用途
BR112022025806A2 (pt) * 2020-06-19 2023-03-07 Fate Therapeutics Inc Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia
WO2022007796A1 (zh) * 2020-07-06 2022-01-13 上海鑫湾生物科技有限公司 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用
EP4185616A1 (en) * 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
CN114276996A (zh) * 2020-09-28 2022-04-05 未来智人再生医学研究院(广州)有限公司 一种表达pd-1/pd-l1阻断物的多能干细胞衍生物及应用
US20230364137A1 (en) * 2020-09-30 2023-11-16 Vor Biopharma Inc. Chimeric antigen receptor expression systems
US20230398215A1 (en) * 2020-10-28 2023-12-14 Sri International Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114525254A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达fgf-21的多能干细胞或其衍生物及应用
CN114517184A (zh) * 2020-10-30 2022-05-20 未来智人再生医学研究院(广州)有限公司 一种表达adipsin的多能干细胞或其衍生物及应用
CN114457025A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达btla阻断物的多能干细胞或其衍生物及应用
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114457031A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达b7-h5阻断物的多能干细胞或其衍生物及应用
CN114457022A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
CN114525258A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
WO2022095902A1 (en) * 2020-11-03 2022-05-12 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
CN114525259B (zh) * 2020-11-03 2025-02-14 南京北恒生物科技有限公司 靶向cd7的嵌合抗原受体及其用途
AU2021372975A1 (en) * 2020-11-04 2023-06-15 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
EP4240832A4 (en) * 2020-11-04 2025-01-01 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114645018A (zh) * 2020-12-18 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
CN114645020A (zh) * 2020-12-21 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达靶向nr4a1抑制因子的多能干细胞及其衍生物与应用
CN114657135A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达Tim-3靶向抑制因子的多能干细胞及其衍生物与应用
US20240117002A1 (en) * 2020-12-23 2024-04-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2022137181A1 (en) * 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
CA3204417A1 (en) * 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
EP4288072A4 (en) * 2021-02-02 2025-10-08 Carisma Therapeutics Inc SELF-POLARIZING IMMUNE CELLS
AU2022228364A1 (en) * 2021-03-05 2023-09-14 Factor Bioscience Inc. Engineered immune cell therapies
BR112023018844A2 (pt) * 2021-04-07 2023-10-10 Century Therapeutics Inc Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
US20240226164A1 (en) * 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
WO2023019185A1 (en) * 2021-08-10 2023-02-16 Gentibio, Inc. Compositions and methods for engineering stable tregs
CN114107378A (zh) * 2021-09-13 2022-03-01 钦元再生医学(珠海)有限公司 一种通用型car-t细胞的制备方法
IL312565A (en) * 2021-11-08 2024-07-01 Fate Therapeutics Inc Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
EP4445136A4 (en) * 2021-12-06 2025-12-31 Wuxi Biologics Ireland Ltd 3D BIOASSESSMENTS FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY MEASUREMENT
CN114414541A (zh) * 2021-12-17 2022-04-29 上海药明生物医药有限公司 一种应用3d细胞成像分析系统检测t细胞杀伤效力的方法
JP2025501617A (ja) * 2021-12-24 2025-01-22 ヘマセル バイオテクノロジー インコーポレイテッド 相同組換え及びインテグラーゼ媒介性組換えによりヒト人工多能性幹細胞を製造する方法
CN114317607B (zh) * 2021-12-31 2024-08-02 苏州桑尼赛尔生物医药有限公司 融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法
WO2023182861A1 (ko) * 2022-03-25 2023-09-28 에이치케이이노엔 주식회사 항-hla-g 키메라 항원 수용체 및 이의 용도
US20250222029A1 (en) 2022-04-08 2025-07-10 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
US20250228943A1 (en) 2022-04-08 2025-07-17 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
CN114478806B (zh) * 2022-04-14 2022-07-01 呈诺再生医学科技(北京)有限公司 一种提升免疫细胞杀伤活性的嵌合受体及其应用
KR20250022772A (ko) 2022-06-09 2025-02-17 우모자 바이오파마 인코포레이티드 Nk 세포 분화를 위한 조성물 및 방법
EP4299734A1 (en) * 2022-07-01 2024-01-03 ETH Zurich Cell line for discovering tcr antigens and uses thereof
AU2023314782A1 (en) 2022-07-27 2025-01-30 Umoja Biopharma, Inc. Differentiation of stem cells in suspension culture
CN116042527B (zh) * 2022-09-07 2023-08-22 广州瑞臻再生医学科技有限公司 一种促进NK细胞分化的iPS细胞系及其构建方法与应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN116445414B (zh) * 2023-03-03 2025-07-08 广州瑞臻再生医学科技有限公司 基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用
CN116410336B (zh) * 2023-06-02 2023-09-22 云南赛元生物技术有限公司 一种嵌合抗原受体的编码核苷酸、car-nk细胞及其构建方法和应用
WO2025146467A1 (en) 2024-01-04 2025-07-10 Onk Therapeutics Limited Targeted il-15 construct delivery
WO2025158400A1 (en) * 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
CN117946973B (zh) * 2024-03-26 2024-05-28 苏州艾凯利元生物科技有限公司 一种CAR-iNK细胞及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524737A (ja) * 2011-06-24 2014-09-25 サイチューン ＩＬ−１５およびＩＬ−１５ＲαＳＵＳＨＩドメインに基づいた免疫サイトカイン
WO2017079673A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
JP2018532729A (ja) * 2015-09-25 2018-11-08 アルター・バイオサイエンス・コーポレーション インターロイキン−１５スーパーアゴニストは、移植片対腫瘍活性を大幅に増強する
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
CN106755107B (zh) * 2016-11-22 2019-10-01 上海健信生物医药科技有限公司 一种car新分子及其在肿瘤治疗中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524737A (ja) * 2011-06-24 2014-09-25 サイチューン ＩＬ−１５およびＩＬ−１５ＲαＳＵＳＨＩドメインに基づいた免疫サイトカイン
WO2017079673A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD (2014) VOL.124, NO.7, PP.1081-1088, JPN6022047895, ISSN: 0005253256 *
CYTOKINE GROWTH FACTOR REV. (2017) VOL.38, PP.10-21 (AUTHOR MANUSCRIPT PP.1-31), JPN6022047898, ISSN: 0004918556 *
EUR. CYTOKINE NETW., vol. 19, no. 1, JPN7023002644, 2008, pages 49 - 59, ISSN: 0005253257 *
J. MOL. BIOL. (2008) VOL.382, PP.1-12, JPN6022047893, ISSN: 0005253254 *
PNAS (2016) VOL.113, NO.48, PP.E7788-E7797, JPN6022047896, ISSN: 0005253255 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545992A (ja) * 2020-10-09 2023-11-01 フェイト セラピューティクス，インコーポレイティド 操作されたｉＰＳＣ及び装備された免疫エフェクター細胞
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
JP2025514709A (ja) * 2022-04-13 2025-05-09 ニューキオ バイオセラピューティクス（シャンハイ）カンパニー，リミテッド 細胞機能を増強するｃｄ１６切断耐性突然変異体

Also Published As

Publication number Publication date
CA3083109A1 (en) 2019-06-13
KR20200097749A (ko) 2020-08-19
KR20260044241A (ko) 2026-04-01
AU2025223849A1 (en) 2025-09-18
IL325617A (en) 2026-02-01
BR112020010597A2 (pt) 2020-10-27
WO2019112899A2 (en) 2019-06-13
WO2019112899A3 (en) 2019-07-18
SG11202004833SA (en) 2020-06-29
AU2018381191B2 (en) 2025-05-29
KR102938303B1 (ko) 2026-03-12
MX2020005477A (es) 2020-11-06
CN111556892A (zh) 2020-08-18
US20210015859A1 (en) 2021-01-21
WO2019112899A8 (en) 2019-08-22
IL275180B1 (en) 2026-01-01
EP3720946A2 (en) 2020-10-14
IL275180A (en) 2020-07-30
EP3720946A4 (en) 2021-08-18
JP2024020364A (ja) 2024-02-14
AU2018381191A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
KR102938303B1 (ko) 향상된 iPSC 유래된 효과기 세포를 사용하는 면역요법
JP7575271B2 (ja) 操作された免疫エフェクター細胞およびその使用
JP7467339B2 (ja) 強化された免疫エフェクター細胞およびその使用
JP2025072543A (ja) 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法
US12275955B2 (en) Combining iPSC derived effector cell types for immunotherapy use
JP2022541441A (ja) 免疫エフェクター細胞操作およびその使用
JP2022527405A (ja) 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成
US20230381235A1 (en) Multiplexed engineered ipscs and immune effector cells targeting solid tumors
KR20230098649A (ko) 조작된 iPSC 및 지속성 면역 효과기 세포
JP2023548829A (ja) 異種腫瘍制御のための操作されたｉＰＳＣ及び免疫エフェクター細胞
KR102883294B1 (ko) 조작된 iPSC 및 보강된 면역 효과기 세포
KR20240031361A (ko) 동종이계 입양 세포 치료를 위한 보호된 이펙터 세포 및 이의 용도
HK40096063A (zh) 靶向实体瘤的多重工程改造的ipsc和免疫效应细胞

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231222

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260427